Related Experiment Video
Updated: Jan 22, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung
Jacob Franek1, Joseph C Cappelleri2, Kelly A Larkin-Kaiser1
1Medlior Health Outcomes Research Ltd, Calgary, Alberta, T2C 5P9, Canada.
Abstract:
Here, we compare the relative clinical efficacy of EGFR-targeted tyrosine kinase inhibitors (EGFR TKIs) for EGFR-positive advanced non-small-cell lung cancer (NSCLC). The authors systematically searched 11 electronic databases from January 2004 to August 2018 for randomized controlled trials measuring clinical efficacy of first-line TKI therapies. Clinical efficacy outcomes included overall survival and progression-free survival. Bayesian network meta-analysis was used to assess the relative efficacy of first-line EGFR TKIs for overall survival and progression-free survival. This network meta-analysis showed that dacomitinib and osimertinib resulted in improved efficacy outcomes compared with afatinib, erlotinib and gefitinib. Both osimertinib and dacomitinib should be considered as standard first-line treatment options for patients diagnosed with advanced EGFR-positive non-small-cell lung cancer.
Insights
Dacomitinib and osimertinib show improved clinical efficacy for advanced EGFR-positive non-small-cell lung cancer (NSCLC) compared to other first-line EGFR tyrosine kinase inhibitors (TKIs). These findings support their use as standard treatments.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Advanced non-small-cell lung cancer (NSCLC) with EGFR mutations presents a therapeutic challenge.
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a key treatment modality for EGFR-positive NSCLC.
Purpose of the Study:
- To compare the relative clinical efficacy of first-line EGFR-targeted tyrosine kinase inhibitors (TKIs) in patients with advanced EGFR-positive NSCLC.
- To identify superior TKI options for first-line treatment based on survival outcomes.
Main Methods:
- Systematic literature search of 11 electronic databases (January 2004 - August 2018).
- Inclusion of randomized controlled trials (RCTs) evaluating first-line TKI therapies.
- Bayesian network meta-analysis to assess overall survival (OS) and progression-free survival (PFS).
Main Results:
- Dacomitinib and osimertinib demonstrated improved efficacy outcomes compared to afatinib, erlotinib, and gefitinib.
- Both dacomitinib and osimertinib showed superior overall survival and progression-free survival benefits.
- The meta-analysis provides a quantitative comparison of first-line EGFR TKIs.
Conclusions:
- Dacomitinib and osimertinib are recommended as standard first-line treatment options for advanced EGFR-positive NSCLC.
- These findings guide clinical decision-making for optimizing patient outcomes.
- Further research may explore long-term efficacy and safety profiles.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...

